WASHINGTON, Oct. 13, 2026 — CVS Pharmacy and related companies have agreed to pay $315 million to resolve federal civil allegations involving opioid and other controlled-substance prescriptions and reimbursement claims submitted to federal health programs, the Justice Department announced Tuesday.
Federal authorities alleged that from October 2013 through December 2025, CVS filled prescriptions that were invalid or lacked a legitimate medical purpose, including certain early refills, excessive doses and hazardous combinations. Prosecutors also alleged that staffing levels and performance policies impaired some pharmacists’ ability to identify and resolve questionable prescribing patterns.
The federal government alleged that many prescriptions described in its complaint were billed to Medicare or other federal healthcare programs. As part of the resolution, CVS entered into an agreement with the Drug Enforcement Administration requiring additional compliance safeguards, including monitoring dispensing patterns, reviewing potentially problematic prescribers and providing a reporting hotline.
The case includes a False Claims Act whistleblower lawsuit brought by a former CVS employee. The settlement resolves civil claims: it is not a criminal conviction, and the Justice Department expressly states that the allegations were resolved without a determination of liability. That procedural distinction applies to the government’s description of CVS’s conduct.
The Justice Department’s announcement links to the Controlled Substances Act and False Claims Act agreements. Readers seeking specific compliance obligations or payment terms should consult those documents.
